Drugs / Raltitrexed
Trials 62 · started per year
today
1
2
2
1
2
1
1
1
1
1
2
3
1
6
2
4
2
4
4
2
6
3
7
2
1
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05007587 | Jul 2021 → Jun 2022 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07349043 | Jan 2026 → Oct 2027 expected | colorectal cancer, peritoneal carcinomatosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT04761185 | Sep 2020 → Dec 2024 | colorectal cancer | Fudan University | Completed | No outcome recorded |
| Phase 1 | NCT00003528 | Sep 1998 → Jun 2002 | childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003109 | Dec 1997 → Oct 2000 | cancer of unknown primary site | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00002902 | Apr 1997 → ? | cancer of unknown primary site | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00002828 | Apr 1995 → Nov 2001 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00001341 | Sep 1993 → Jun 2001 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05426811 | Jul 2022 → Jul 2025 | colorectal neoplasm | China Medical University, China | Unknown | No outcome recorded |
| Phase 242 trials | ||||||
| Phase 2 | NCT07327788 | Dec 2025 → Dec 2027 expected | hepatocellular carcinoma, portal vein thrombosis | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06812039 | Jan 2025 → Dec 2026 expected | hepatocellular carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06665087 | Nov 2024 → Nov 2027 expected | colon carcinoma, rectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06652412 | Nov 2024 → Nov 2027 expected | colon carcinoma, rectal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06475287 | Jul 2024 → Jul 2025 overdue | hepatocellular carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06441019 | Jul 2024 → May 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT06397235 | May 2024 → Apr 2027 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06423937 | May 2024 → Jul 2026 overdue | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06427005 | Feb 2023 → Aug 2025 | — | Meng Qiu | Unknown | No outcome recorded |
| Phase 2 | NCT05628038 | Nov 2022 → Dec 2024 overdue | rectal carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06239532 | Sep 2022 → Dec 2024 overdue | intrahepatic cholangiocarcinoma | Qilu Hospital of Shandong University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05435313 | Jul 2022 → Jan 2024 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05361161 | Jun → Dec 2022 | gastric cancer | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT05340231 | May → Dec 2022 | colorectal cancer | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT05160896 | Nov 2021 → Jun 2023 | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT04597970 | Oct 2020 → Oct 2021 | hepatocellular carcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04582981 | Sep 2020 → Jun 2023 | colorectal carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05148143 | Jun 2020 → Dec 2022 | bile duct adenoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT04241731 | Nov 2019 → Nov 2021 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04581876 | Nov 2019 → Sep 2022 | malignant pancreatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03813641 | Jan 2019 → Feb 2021 | colorectal cancer | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04499586 | Jan 2019 → Aug 2020 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03585530 | Sep 2018 → Jan 2022 | esophageal squamous cell carcinoma | Huai'an First People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03485027 | Jan 2018 → Dec 2022 | chemotherapy-induced toxicity, colorectal cancer | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT03344614 | Jul 2017 → Jan 2019 | colorectal cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03126071 | Feb 2017 → Aug 2022 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03392103 | Jan 2017 → Dec 2019 | gastric cancer | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03053167 | Dec 2016 → Dec 2019 | colorectal cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT02992886 | Sep 2016 → May 2021 | rectal cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02618356 | Dec 2015 → Nov 2017 | malignant colon neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT02562599 | Aug 2015 → Dec 2016 | nasopharyngeal carcinoma | Hubei Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03083613 | May 2015 → Sep 2017 | gastric cancer, gastroesophageal junction adenocarcinoma | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02376452 | Sep 2014 → Dec 2015 | colorectal carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT02072317 | Nov 2013 → Mar 2016 | gastric cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01836120 | Apr 2013 → Dec 2016 | gastric cancer | Hebei Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01732380 | Jul 2012 → Jul 2013 | esophageal cancer | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
| Phase 2 | NCT02821559 | Jul 2012 → Aug 2014 | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT01532804 | Jul 2011 → May 2016 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Terminated | No outcome recorded |
| Phase 2 | NCT01348412 | Dec 2010 | metastasis from malignant tumor of colon | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| Phase 2 | NCT02723253 | Jan 2005 → Jan 2008 | rectal cancer | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
| Phase 2 | NCT00590278 | Aug 2002 → ? | rectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00004254 | Nov 1999 → Jun 2001 | malignant mesothelioma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00234429 | Nov 2003 → Jun 2006 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05766605 | Jan 2023 → Jan 2026 | hepatocellular carcinoma | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02453490 | Oct 2015 → Sep 2018 | metastasis from malignant tumor of colon | Zhejiang University | Terminated | No outcome recorded |
| Phase 3 | NCT02485548 | Jun 2015 → Jun 2018 | head and neck squamous cell carcinoma | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00004920 | Nov 1999 → Jan 2003 | malignant mesothelioma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00002893 | Jun 1995 → ? | colorectal cancer | Medical Research Council | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06118762 | Oct 2023 → Oct 2026 expected | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 4 | NCT03196843 | Sep 2017 → Aug 2020 | head and neck squamous cell carcinoma | The First Affiliated Hospital of Dalian Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02557490 | Jan 2015 → Dec 2016 | metastasis from malignant tumor of colon | Zhu Xu | Unknown | No outcome recorded |
| Phase 4 | NCT01959061 | Sep 2013 → Dec 2017 | colorectal cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06519578 | Aug 2024 → Jul 2026 overdue | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06525428 Background | Apr 2024 → Dec 2026 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06841159 Background | Mar 2024 → Mar 2026 overdue | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT03823079 Background | Feb → Sep 2019 | colorectal carcinoma, thrombocytopenia | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01481545 Background | Dec 2006 → Jul 2011 | rectal cancer | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05701436 Background | Sep 2022 → Jan 2026 | liver cancer | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02678806 Comparator | Nov 2017 → Nov 2018 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 71 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | raltitrexed | “Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT),...” NCT06841159 ↗66“transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)” NCT04597970 ↗ “The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.” NCT05007587 ↗ “RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour.” NCT06397235 ↗ “Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.” NCT05361161 ↗ “Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1” NCT03485027 ↗ “The chemotherapy regimen consists of oxaliplatin 85 mg/m² over 2 hours and raltitrexed 2 mg/m² over 1 hour.” NCT06812039 ↗ “TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2）” NCT06423937 ↗ “Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery.” NCT02678806 ↗ “Oxaliplatin 85 mg/m² over 2 to 4 hours, and Raltitrexed 3 mg/m² over 1 to 2 hours” NCT07327788 ↗ “Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours.” NCT06239532 ↗ “Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg)” NCT05340231 ↗ “Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle” NCT06118762 ↗ “Raltitrexed is a potent thymidylate synthase (TS) inhibitor.” NCT02821559 ↗ “15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2” NCT02723253 ↗ “FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab” NCT06525428 ↗ “Raltitrexed 3 mg/m\^2” NCT06519578 ↗ “Raltitrexed” NCT01703910 ↗ |
| Known as | raltitrexed for injection | “Drug: raltitrexed for injection” NCT04581876 ↗ |
| Known as | Tomudex | “We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II...” PMID 12565988 ↗ Feb 20033“15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2” NCT02723253 ↗ “ZD1694 (TOMUDEX)” NCT00001341 ↗ |
| Known as | ZD-16 | ChEMBL registry synonym — accepted as the source's own label CHEMBL225071 ↗ |
| Known as | ZD1694 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001341 ↗ |
| Action | Inhibit | “Thymidylate synthase inhibitor” CHEMBL225071 ↗1“directly inhibits TS” NCT00001341 ↗ |
| Modality | Small molecule | “new quinazolone folate analog” NCT00001341 ↗ |
| Route | Intravenous | “administered as a 15 minute IV infusion” NCT00001341 ↗ |
| Target | TYMS | “Thymidylate synthase inhibitor” CHEMBL225071 ↗ |